Helping patients reclaim a life of possibility
More than 65 per cent of people living with an oncohaematological disease experience a deterioration in their employment and financial situation. This is one of the key findings of a report developed and presented by AELCLÉS, one of the Spanish members of Myeloma Patients Europe (MPE). According to the report, over 65 per cent of…
On 13–14 December in Warsaw, the Carita Foundation hosted its Hemato-Oncology Patient Forum, bringing together 150 participants including patients, clinicians, pharmaceutical representatives and volunteers. The event marked the 15th anniversary of the Carita Foundation and the 35th anniversary of the International Myeloma Foundation (IMF), which co-organised the Forum alongside MPE. The programme featured international experts and…
Last week Myeloma Patients Europe (MPE) submitted a response to the European Medicines Agency (EMA) open consultation on their “Reflection paper on patient experience data (PED)”. PED refers to data from patients that includes their perspectives, preferences and experiences with different aspects of their disease and treatments, such as quality of life and risk tolerability,…
Myeloma patients may receive many different treatments throughout their care. Patients’ real-world experiences of treatments tell us how treatments work in everyday life. Myeloma Patients Europe (MPE) wants to hear from myeloma patients about their experiences with some particular treatments: Bispecific antibodies (such as teclistamab or elranatamab) CAR T-cell therapy (such as cilta-cel or ide-cel) Antibody–drug conjugates (such as…
The US Food and Drug Administration (FDA) has issued draft guidance to the pharmaceutical industry on using minimal residual disease (MRD) and complete response (CR) in myeloma clinical trials as a primary endpoint, to support approval under accelerated assessment. This follows a previous decision of the US FDA’s Oncology Drugs Advisory Committee (ODAC) to accept…
The largest haematology meeting in the world has just finished. The American Society of Hematology (ASH) Annual Congress took place in Orlando, Florida, US, where the latest research in blood diseases was presented. Myeloma Patients Europe (MPE) interviewed key experts to learn more about the most relevant studies and abstracts in myeloma and AL amyloidosis.…
From 6-9 December Myeloma Patients Europe (MPE) attended the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. Over 20,000 researchers, doctors, nurses and patient advocates attended the meeting to share and discuss the results of the latest research from across blood cancers. ASH was a great way to close out another successful year…
We are delighted to share MPE’s Year in Review 2025, a summary of what we have achieved this year alongside our many collaborators. This year we have strengthened partnerships, welcomed new members into our community and made progress on the European advocacy issues that matter most to patients and their families. We have worked together…